INTRODUCTION
Gene transfer and antisense therapy offer novel approaches to the study and treatment of vascular diseases. Initially designed to correct inherited disease, gene therapy has found new applications in the field of vascular pathologies. The localized nature of major vascular diseases like coronary artery restenosis after angioplasty has made the limited application of genetic material an attractive therapeutic option. Thus, smooth muscle cell proliferation, a major mechanism involved in the coronary restenosis, can be prevented by gene or antisense therapy in animal models. In peripheral arterial diseases, therapeutic angiogenesis by gene transfer is an alternative approach for the treatment of critical limb ischemia. Numerous pharmacological approaches, including antiplatelet agents, anticoagulants, angiotensin-converting enzyme antagonists and cytotoxic drugs, have failed to inhibit restenosis. In vascular peripheral diseases, there is inadequate evidence to support the routine use of primary pharmacological treatment in patients with critical leg ischemia. Thus, gene therapy may offer pharmacodynamic and pharmacokinetic advantages compared to conventional therapy such as specific distibution of the drug (gene) to the site of the disease by delivery systems or tissue specific promoters and long lasting effect, with the gene product being synthesized as long as the gene is expressed in the transfected cells.
TRANSFER OF NUCLEOTIDES INTO THE VASCULAR WALL
One of the main challenges in gene transfer is the introduction of nucleotides into the host cells. Hence, methods have been developed to transfer foreign DNA or RNA into cells. Viral and nonviral vectors have been employed in vascular gene transfer studies to overcome the natural resistance of vascular cells to foreign nucleotides, thus facilitating the delivery and entry of the recombinant genetic material into these cells. Vectors include viral vectors, such as retrovirus and adenovirus, and nonviral vectors, such as cationic liposomes, liposome viral conjugates, plycations and polymer gels.
viral vectors
Viruses have received considerable attention as DNA carriers because of their efficient infection of host cells. Several types of viruses, including retroviruses and adenoviruses, are used for gene delivery.
Retroviruses
Retroviruses are efficient vectors in eukaryotic cells for several reasons. The retrovirus life cycle involves several steps that facilitate the uptake and expression of foreign genes in the host cells, including reverse transcription of the viral RNA, integration of the complementary DNA into the host genome and expression of the viral genes by the infected cell. This ability of the retrovirus vector to become part of the host genome could be hazardous for the host cells if the production of the virus is not controlled. Retroviruses are thus rendered replication incompetent by removal of the structural genes necessary for replication. Synthesis of the viral particles is accomplished using a packaging cell line that contains the missing genes for replication. Virus stock is used to infect host cells, resulting in integration of viral genome and stable gene expression of the new gene.
Retrovirus-mediated gene transfer has been used for cell-mediated gene transfer into endothelial cells (Dichek et al, 1989 ; Nabel et al, 1989; Wilson et al, 1989 ; Conte et al, 1994) and hepatocytes (Grossman et al. 1994) and direct gene transfer in pig arteries (Nabel et al, 1990; 1992) . Despite the relative ease with which stable retroviral infection is accomplished in many cell types, the efficiency of gene transfer in vascular cells via retroviral vectors is relatively low. Approximately 5 to 10% of rat, porcine or bovine endothelial cells have been infected in vitro, while 0.1 to 1% of endothelial cells have been infected in vivo (Nabel et al, 1990; Leclerc et al, 1992) . In addition, retroviral vectors are only effective in replicating cells, thus limiting the using of this vector in quiescent vascular cells.
The safety concerns regarding gene transfer when using retroviral vectors is dominated by the risk of mutations linked to the integration of a foreign DNA into the host cell genome, particularly when using retroviruses with viral oncogenes. In a preclinical animal study, three of eight immunosuppressed monkeys developed a T cell lymphoma 6 months following gene transfer in bone marrow stem cells using a retroviral vector. The lymphoma was the result of a contamination of the vector stock by a wild-type virus (Kolberg, 1992 ). In contrast, 5 month studies of porcine serum and peripheral blood lymphocytes derived from direct reviral gene transfer studies in porcine arteries have revealed no wild-type recombination (Nabel et al, 1990 ).
In summary, retroviral vectors are low efficiency vectors in vascular cells in vivo. Integration into the host genome results in stable gene expression over a period of months (Nabel et al, 1990) . Because retroviral vectors infect replicating cells, application to quiescent cells is limited. Finally, the safety of direct gene transfer in vivo using retroviral vectors has not been completely determined.
Adenoviruses
In order to develop more efficient vectors for vascular gene transfer, many investigators have employed replication-defective adenoviral vectors. Recombinant adenoviruses have several properties that make them attractive vectors for in vivo gene delivery, including infectivity for numerous cell types, high transfection efficiency and absence of mutagenicity. However, several issues relevant to application to human therapies, including stability of gene expression, host cell immune response, transmission to germline cells and toxicity, have not been systematically studied.
The human adenovirus is a nonenveloped, icosahedral, double-stranded DNA virus of 37 Kb (reviewed in Horwitz, 1991) . There exist more than 100 different serotypes of adenovirus in mammalian species and 49 in humans. Adenoviruses infect a broad range of mammalian cells by attachment to a cell surface glycoprotcin receptor through the fibrous component of its capsid. The mechanism by which the adenovhs enters a cell is not completely known and presumably occurs via receptor-mediated endocytosis. The viral genome escapes lysosomal degradation due to a terminal protein covalently linked to the terminal regions of the genome. Following release from the cytoplasm, the viral genome translocates to the nucleus but is not integrated in the host genome. It remains in the nucleus as an episome. Exuachromosomal location of the virus greatly reduces the chances of mutation by random integration and dysregulation of important host regulatory genes.
Adenovhses type 2 and 5 are currently used for gene therapy. Adenoviral vectors are constructed by insertion of foreign genes into one of three locations, replacing the early regions 1 or 3 (El or E3), or as an insertion between the E4 region and the end of the genome (reviewed in Horwitz, 1991; Gerard and Meidel, 1993; Kozarsky and Wilson, 1993 (Lemarchand et al, 1992 ) and cardiomyocytes (Kass-Eisler et al, 1993 ) with a high rate of gene transfer. In vivo adenovirus-mediated gene transfer has been performed in carotid and jugular veins (Lemarchand et al, 1993) . rat myocardium (Kass-Eisler et al, 1993) . rabbit peripheral arteries (Steg et al, 1994; Feldman et al, 1995; Simari et al, 1996) and ex vivo in saphenous veins (Chen et al. 1994) . Several adenovirus-mediated gene therapy strategies aiming to reduce cell proliferation have been conducted successfully in the vessel wall, including transfer of the herpes simplex virus thymidine kinase gene (Ohno et al, 1994; Chang et al , 1995b; Simari et al. 1996) . a nonphosphorylated form of retinoblastoma (Rb) gene (Chang et al, 1995b) . and the inhibitory cell cycle protein p21 (Chang et al. 1996; Yang et al, 1996) .
Main limitations of adenovirus-mediated gene transfer include immunogenicity and cell toxicity. Adenoviral infection of experimental animals can result in humoral and cellular immune responses to the vector and vector-infected host cells (Wilson, 1996) . Adenoviruses as gene-delivery vehicles can lead to the synthesis of neutralizing antibodies directed against viral capsid proteins as well as the expressed foreign gene which may decrease the amount and length of gene expression and hamper a second administration (Kass-Eisler et al, 1994) . The duration of the gene expression in several animal models appears to be limited to 3 or 4 weeks (Lemarchand et al, 1993; Steg et al, 1994) . In addition, limited gene expression may be due to loss of genome or extinction of the promoter.
Administration of wild-type replication-competent adenoviruses have been associated with inflammatory phenomena in the lung and the liver in animal models (Hen. and Gerard, 1993; Prince et al, 1993) . In balloon-injured rat carotid arteries, dose-response studies of adenovirus efficacy and toxicity have shown that maximum recombinant gene expression was produced by virus concentrations ranging from 2 x 1010 to 5 x 1010 pfu/mL, without significant toxic effects on the arterial wall. Infusion of the adenovirus at high titers (1011 pfu/mL) resulted in decreased gene expression and local toxicity (Schulick et al, 1995) . In a rabbit model of gene transfer into normal arteries, exposure to adenovirus vectors (2 x 1010 pNmL) resulted in a pronounced infiltration of T cells throughout the arterial wall, an upregulation of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in arterial smooth muscle cells and a neointimal hyperplasia . Several mechanisms are proposed for the adenovirus toxicity: the expression of a viral protein, like the E4 product, can induce cytopathic effects; the host immune reponse directed toward the virus leads to inflammation; infection of cells at high level of multiplicity of infection can induce toxicity (the cell toxicity of the viral capsid, basepenton, is demonstrated in vitro).
An additional disadvantage is size limitation. DNA inserts larger than 10% of the viral genome size may not be packaged by the virus. In practice, adenoviral vectors encoding nucleotide sequences longer than 3.5 Kb are difficult to construct (Gerard and Meidel, 1993) .
First generation recombinant adenovirus vectors, utilizing a deletion of El genes and partial deletion of E3 gene have been useful for in vivo applications of gene transfer. However, gene expression has been transient and associated with immunogenicity best characterized in the mouse, and lung inflammation in human studies. In an attempt to limit these side effects, new strategies of cloning have been used. The E2 region of the adenovirus genome appears to be involved in stimulating the immune response as well as promoting a local inflammatory process. Adenoviruses in which the E2A gene has been mutated induce less inflammatory response and are associated with longer gene expression in the mouse lung and liver Yang et al, 1994) .
Nonviral vectors
Nonviral vectors have been developed over the past several years in an effort to reduce the potential risks of viral-mediated gene transfer, particularly for human application. Effective nonviral vectors include liposomes, calcium phosphate, electroporation, DEAE-dextran and polycations.
Liposomes
Liposomes are self-assembled colloidal particles in which a lipid bilayer encapsulates some of the surrounding aqueous medium (Lasic and Papahadjopoulos, 1995) . Since their original description, liposomes have been discussed as vehicles that could be used as carriers of pharmaceutically active agents. However, their medical utility appeared to be limited by their rapid uptake by phagocytic cells of the immune system. predominantly in the liver and spleen (Lasic and Papahadjopoulos. 1995) . Interest in liposomes was rejuvenated by their ability to deliver nucleic acids into cells. Thus. liposomes were capable of encapsulating DNA, then fusing with the cell membrane and delivering the polynucleotides into the cytoplasm (Felgner, 1990) . Although liposome-mediated transfection methodology is notable for its simplicity, several technical difficulties slowed the development of this technology, including the poor efficiency of conventional liposomes to package DNA (size limitation) and extensive lysosomal degradation of the liposome and the encapsulated polynucleotide (Felgner. 1990 ). In the late 1980s. cationic liposomes were developed in order to overcome some of these deficiencies. Cationic liposomes have been employed to deliver DNA, RNA and antisense oligonucleotides to a variety of cells (Felgner et al, 1987) . The rationale for synthesis of cationic liposomes and their use as polynucleotide delivery agents stems from the observation that DNA and all biological surfaces, including cell membranes, are negatively charged (nucleic acids) or have a relatively negative charge (biological surfaces) (Felgner, 1990 ). In the DNA-cationic liposome complex, the nucleic acids are not encapsuled but are simply complexed with small unilamellar vesicles by electrostatic interaction (Felgner et al, 1987) . The supramacromolecule then interacts spontaneously with the negatively charged cell membrane and delivers the nucleic acids into the membrane. Although the interactions between the lipid-DNA complex and the cell membrane are not completely understood, the process yields efficient transfection of many of the cells and tissues.
Cationic liposome reagents are a growing class of compounds that are useful for the transfection of cells in vim and for gene delivery in vivo. The prototype cationic lipid, DOTMA. mixed with a neutral lipid DOPE, is commercially available as Lipofectin@ (GIBCO-BRL, Gaithersburg, MD. USA) (Felgner and Ringold. 1989) . Improvements have reduced toxicity and increased transfection efficiency. Examples of second generation cationic liposomes include DOSPNDOPE. commercially available as Lipofectaminea (GIBCO-BRL).
The interactions between the cationic liposome-DNA complex and the cell membrane are based on electrovalent interactions. The molar ratio between the DNA and the cationic liposome is therefore a critical parameter for the reagent's efficacy (Felgner and Ringold, 1989) . Theoretically. the optimal ratio should be such that the amount of positive charge contributed to the cationic liposome slighty exceeds the number of negative charges on the DNA, so that the complexes have a net positive charge to facilitate their interaction with the negatively charged target cell surface (Felgner and Ringold, 1989; Stephan et d, 1996) . In practice, differences in target cell, plasmid DNA and liposome preparations require adjustments of the lipid to DNA ratio and absolute concentrations to optimize transfection efficiency (Stewart et al. 1992; San et al, 1993; Stephan et al, 19%) .
Cationic liposomes have been employed in animal models of vascular diseases, including peripheral arteries in the pig (Nabel et al, 1990 (Nabel et al, . 1992a (Nabel et al, , 1993a .b.c) and coronary vasculahue (French et al, 1994; Shi et al, 1994) . Like retroviral vectors, however, cationic liposomes are low efficiency vectors in vascular cells (Nabel et al, 1990 ). In addition, the duration of expression seems to be limited to 4 weeks (Nabel et al, 1990) . Further modifications to the chemical formulation of cationic liposomes appear promising in terms of improving transftction efficiency. A major advantage of cationic liposomes is safety. In studies of direct gene transfer mediated by cationic liposomes. gene expression was limited to the site of gene introduction. and organ toxicity (including the gonads) as well as biochemical and hematologic changes, have not been observed (Stewart et al. 1992; San et al, 1993; Stephan et al, 1996) . Table I (Morishita et al, 1993a) . nitric oxide synthase gene (Leyden et al, 1995) or antisense oligonucleotides into rat carotid arteries (Morishita et al, 1993a; .
Pobmer gels
Arterial gene transfer has been perfomed during balloon angioplasty by delivery of naked DNA from a thin coat of hydrogel polymer applied to a standard angioplasty balloon. This method applied in rabbit arteries in vivo resulted in a S 0.1% frequency of transfected cells. Gene expression in cells was observed mainly in intima or subintima (Riessen et al, 1993) . Pluronic gel has been employed to deliver antisense oligonucleotide to the external and internal surfaces of the arteries (Simons et al, 1992; Bennet and Schwartz. 1995 (Nabel et al. 1989) . rabbit arteries (Conte et al, 1994) . prosthetic vascular grafts (Wilson et al, 1989 ) and reimplanted in vivo on steel stents (Dichek et al, 1989) . Gene expression lasted at least 4 weeks in peripheral arteries (Nabcl et al, 1989) and 5 weeks in prosthetic grafts (Wilson et al, 1989) .
A potential role for ex vivo vascular gene transfer may be enhancing fibrinolysis within vascular devices highly predisposed to thrombosis, such as stents and prosthetic grafts. In one study, a human t-PA gene was transfected into sheep endothelial cells which were then seeded onto stainless steel stents. Endothelial cells replicated, covering the stents. Secretion of t-PA was demonstrated from cells before and after the transduced cells were implanted onto the stent (Dichek et al, 1989) . Genetically modified smooth muscle cells expressing human adenosine deaminase have been seeded onto rat carotid arteries. inducing a local production of the recombinant protein (Lynch et al, 1992) .
The direct introduction of nucleotides into vascular cells, in situ, is a compelling modality for several reasons (Nabel and Nabel, 1994) . Direct gene transfer is less complex and requires less sophisticated technology compared with cell-mediated gene transfer. Direct gene transfer is less disruptive to the normal architecture of the vessel. for example, endothelial denudation is not performed prior transfection. Historically, the feasibility and specificity of direct gene transfer was demonstrated using a recombinant nonreplicative retrov k expressing a reporter gene, beta-galactosidase. in pig arteries (Nabel et al, 1990) . Since then, direct gene transfer has been achieved in normal, injured and atherosclerotic arteries using recombinant adenoviruses or liposomes (Nabel et al, 1990; Simari et al, 1996) .
DELIVERY SYSTEMS
Interest in gene therapy for vascular disease is generated by the localized nature of the disease, rendering these lesions accessible to direct gene infusion via catheters. Intravascular catheters have been developed and modified to fit the different anatomical locations allowing gene delivery in various situations. For instance, coronary arteries cannot be occluded for a long time, and special devices allowing continuous perfusion downstream of the lesion are being developed. Currently, several local drug delivery catheters have been evaluated in animal models, including a double balloon catheter, a standard porous balloon catheter, a hydrogel-coated catheter and a channel balloon catheter. The double balloon catheter consists of two independently inflatable balloons located proximal and distal to the connecting shaft, which permits infusion of catheter contents. Inflation of the balloons creates a central infusion chamber for gene transfer (fig 1) . Genetic material has been successfully delivered into peripheral arteries using this catheter (Nabel et al, 1989 (Nabel et al, , 1990 (Nabel et al, , 1992a (Nabel et al, . b, 1993a San et al. 1993; Ohno et al. 1994; Steg et al. 1994; Chang et al, 1995a) .
Catheters containing pores on the surface of the balloons have been developed to deliver solutions locally to sites with lesions. Instillation of solutions under pressure is performed through these pores into the arterial wall. Transfer of genes has resulted in variable gene expression associated with vascular injury in the arterial wall. Focal jet sprays may form at the site of the pores, creating areas of intimal disruption, medial dissection and subintimal haemorrhage.
The hydrogel catheter is a standard angioplasty catheter covered with a hydrogel coating that acts to absorb hydrophilic agents (Riessen et al. 1993; Steg et al, 1994; Isner et al. 1995) . Polynucleotides are applied to the gel-coated balloon. When the balloon is inflated in an artery, the nucleotide is pressed into the arterial wall. One disadvantage of the hydrogel catheter is that the nucleotide can be rapidly washed off the balloon after exposure to the bloodstream, so protective sheaths may be required during the transport in the arterial circulation. The channel balloon catheter contains multiple external channels circumferentially arranged around an angioplasty balloon. The inflation pnssure necessary to inflate the balloon is separated from the hydrostatic pressure needed to infuse nucleotides. The channels, containing pores, are placed against the arterial wall by inflation of the inner balloon and thereafter, intramural delivery can occur independently through the pores (Feldman et al. 1995) .
GENE TRANSFER AND ANTISENSE APPROACHES TO THE TREATMENT OF VASCULAR DISEASES Vascular proliferation: the restenosis paradigm
Percutaneous transluminal coronary angioplasty (PTCA) remains a mainstay of therapy for symptomatic coronary artery disease (Landau et al, 1994) . While this procedure is initially successful in relieving critical arterial stenoses in more than 90% of patients, a reactive smooth muscle cell (SMC) proliferation ensues within the first 6 months after the procedure, leading to clinically significant intimal hyperplasia in 30 to 50% of the treated arteries (Schwartz et al, 1992) . The pathophysiology of restenosis is complex and multiple factors contribute, including thrombus formation, smooth muscle cell proliferation and extracellular matrix synthesis and recoil of the vessel wall (Nabel et al, 1994) . Recent findings have suggested that restenosis may be related, at least in part, to reactive-adaptative remodeling processes including those by which blood vessels tend to compensate for plaque formation (including artery enlargement as plaques form), thereby preserving lumen cross-section area for an extended period (Glagov et al. 1987 ). Disruptions. introduced by angioplasty, result in local and focal redistributions of both wall shear stress and mural tensile stress and elicit adaptative modeling reactions in intima. media and plaque. These changes will appear as alterations of lumen configuration, lumen radius and overall artery size. Regulation of this response is closely related to the interaction between local circulatory stimuli and the tissue responses which tend to maintain or restore baseline flow conditions (Glagov, 1994 Group, 1992) . Stents have reduced the clinical incidence of coronary artery restenosis and the role of cellular proliferation in restenosis of stents is under investigation. The localized nature of restenosis has made the local application of highly concentrated pharmacological agents or genetic material an attractive therapeutic option. Local delivery of pharmaceutical compounds again was not successful, mainly because of the short term of retention in the vessel wall. More recently, genetic approaches have been used both to better understand the molecular mechanisms underlying the SMC proliferative response to arterial injury and to form the basis for novel gene-based therapies for restenosis and other vascular proliferative diseases (Nabel et al, 1993~; Ohno et al, 1994; Chang et al, 1995b; Chang et al, 1996) . Furthermore, gene transfer of vectors which are taken up by the targeted cells provide prolonged local expression of their gene product.
Animal modelk of restenosk Intimal cell proliferation is an important pathophysiological event in the restenosis process. It is moreover an accessible target for antiproliferative gene therapy. Animal models have been designed to reproduce human atherosclerotic lesions. However, there are significant differences between the models and their fidelity to human vascular lesions. Three animal species, the rat, the rabbit and the pig, are commonly used in restenosis studies. Results among these species have been shown to differ significantly, raising issues of suitability of animal models for human restenosis.
The rat carotid model has been widely used (Lynch et Chang et al, 1996) . An endothelial denudation of the common carotid artery is performed with a Fogarty balloon catheter. The balloon catheter is introduced into the external carotid artery and passed several times with the balloon distended sufficiently with air to generate slight resistance and remove the endothelium. This endothelium denudation induces a strong neointimal SMC proliferation with matrix production. In this model, SMC migration and proliferation is a major feature of the development of intimal thickening. It appears that the rate of SMC proliferation in this model exceeds SMC proliferation in human lesions. Pharmacological therapies which effectively inhibited intimal SMC proliferation in this model were not successful in human restenosis, raising questions about extrapolation of results obtained in the rat carotid artery to human vascular diseases. For example, the gene transfer of type 2 angiotensin I1 receptors increases neointimal formation in the injured rat carotid model (Nakajima et al, 1995) . Conversely in the same model, antagonists of type 2 angiotensin receptors prevents the neotintimal thickening after injury, but fails to demonstrate the same effect in the pig coronary artery (Huckle et al, 1996) . Thus, several reports have demonstrated the ability of angiotensin-converting inhibitors to block the neotintima formation in the rat but attemps to duplicate these results, namely in human restenosis, have failed (MERCATOR Group, 1992) . Finally, an additional limitation of this model is the difficulty to develop atherosclerotic lesions in the rat.
Catheter-mediated arterial injury and cholesterol feeding in rabbits result in the development of atherosclerotic lesions characterized by foam cells, inflammatory infiltrates and intimal cell D Steghn. ui N&el proliferation (Leclerc et al, 1992; Conte et al, 1994; Steg et al, 1994; Takeshita et al. 1994; Newman et al, 1995; Feldman et al, 1995; Simari et al. 1996 ). An atherosclerotic lesion is created by endothelial denudation using a Fogarty catheter combined with a high cholesterol diet. Several weeks after the first injury a balloon angioplasty is performed at the same site. Continual intimal thickening follows and treatments can be tested on the developing lesion. An advantage of this model is that arterial lesions with foam cell infiltration develop within 3 weeks of cholesterol feeding; however, morphological features of these lesions do not mimic human arteriosclerosis. The lipid content of these plaques is significantly higher than in human plaques. This particular aspect of the atherosclerosis induced in rabbits may explain the efficacy of lipid-lowering drugs in this model (Gellman et al. 1991) .
These drugs failed to demonstrate the same effect in the human coronary restenosis (Sahni ct al. 1991). Several strategies have been studied in this rabbit model. including the gene transfer of the herpes virus thymidim kinase (Simari et al, 1996) .
In the pig. normal and balloon-injured iliac armies (Nabel ct al, 1989 (Nabel ct al, . 1990 (Nabel ct al, , 1992a (Nabel ct al, . b. 1993a (Ohno t t al, 1994) . Limitations to studies in pigs include the cost and housing of the animals and the length of time (12 to 18 months) needed to develop atherosclerotic lesions following cholesterol feeding.
Vascular gene transfer has also been employed to study mechanisms of intimal cell proliferation following expression of growth factor genes in vivo. The effects of growth factors. including platelet-derived growth factor (PDGF) (Nabel et al, 1993b) . fibroblast growth factor-1 (FGF-1) (Nabel ct al, 199%) and transforming growth factor-pl (TGF-PI) (Nabel et al, 1993a), have been studied on the development of neointima in arteries. Recent data from human atherosclerosis specimens and gene targeting studies suggest an important rde for these growth factors in human vascular disease. including atherosclerosis and restenosis (Nabel and Nabel, 1994) . Lipsomemediated transfection of a plasmid expression vector encoding human PDGF B, secreted FGF-I (acidic FGF), secreted active TGF-PI, or a reporter gene was performed into porcine iliofemoral arteries using a double balloon catheter. Transfection of PDGF B was sssociated with intimal thickening, characterized by inmased cellularity and smooth muscle cell proliferation. in contrast to the control artery transfected with a reporter gene (fig 2) (Nabel ct al, 199%). Transfcction of a plasmid encoding a secreted form of FGF-I was associated with intimal thickening. However, in vessels with expanded intima, n e o c~-pillaries were observed within the intima (Nabel  et al, 1993a) . TGF-PI expression was sssociated with a significant increase in procollagen synthesis in the intima and media that resulted in an intimal and medial thickening (Nabel et al, 1993b) .
may have overlapping but distinct effects on amrial pathology and may guide the development of molecular genetic interventions to limit intimal hyperplasia following balloon injury (Nabel and Nabel, 1994) . Several gene and other biological approaches have b a n used sucoessfully to prevent intimal cell proliferation in animal models, including transfer of genes encoding for herpes simplex vim-thymidine kinase (HSV-tk) (Ohno ct al. 1994. Chang et al, 1995b; Simari et al, 1996) . a constitutively active form of retinoblastoma (Chang et al. 1995a ), a cyclin-dependent lrinase inhibitor, p21 
HSV& lmnsferandganc&lovirtrmtnwnt
One approach to the selective elimination of dividing cells is to express a HSV-tk gem, which converts a nucleoside analog prodrug. ganciclovir, into an active toxic form in transduccd cells (Bomlli et al, 1988 1995b; Simari et al, 1996) . In these studies.
adenoviral vectors encoding the HSV-tk were introduced into balloon-injured arteries at the time of the injury. Ganciclovir (25 to 50 mgkg) was administrated 24 to 36 hours after infection These data suggest that three growth factor genes gonuckotidethercrpy. for 6 days. Three weeks after balloon injury and adenoviral infection, the areas of the intima and media in each arteries were measured by quantitative morphometry. and the intimal to medial ( I N ) area ratio were determined. A significant reduction in the I/M area ratio was observed in vessels subjected to injury in animals transduced with HSV-tk and treated with ganciclovir, compared with control animals (fig 3) . The potential for systemic toxicity following adenoviral transfection of HSV-tk and treatment with ganciclovir was investigated by analysis of serum biochemistry and pathological examination of the main organs. None of the treated animals showed evidence of hematologic or organ toxicity. These studies demonstrate the potential utility of a molecular intervention targeted to proliferating smooth muscle cells after balloon injury. Whether this type of strategy might be effective in treating human vascular proliferative disorders awaits further confirmation.
CeU cyck inhibition
Redundancy in growth factor signaling pathways has led to the suggestion that effective therapies for vascular proliferative diseases should target nuclear cell cycle regulatory pathways rather than more proximal signal transduction molecules. 
ADV-tk/-GC
A DV-t k/+ G C cell cycle have been investigated in vascular models: transfer of a nonphosphorylated form of Rb (Chang et al, 1995a ) and transfer of a CDK inhibitor, p21 (Chang et al, 1996; Yang et al, 1996) . The retinoblastoma gene product (Rb) is present in an unphosphorylated and inactive form in quiescent arterial SMCs, but is rapidly activated by phosphorylation in response to growth factor stimulation in vitro. Localized arterial infection with a recombinant adenovirus encoding a nonphosphorylatable form (constitutively active form of Rb) in injured arteries significantly reduced the SMC proliferation and neointima formation in rat carotid and pig femoral arteries (Chang et al, 1995a) .
P21 is a negative regulator of cell cycle propssion by inhibition of CDKs required for the initiation of the S phase, and by binding to and inhibiting the proliferating cell nuclear antigen (FCNA). Adenovirus-mediated overexpression of human p2 1 inhibits growth factor-stimulated SMC proliferation in vitro by arresting SMCs in GI phase of the cell cycle. Localized infection of injured arteries with a p2 1 -encoding adenovirus significantly reduced neointimal hyperplasia in the rat carotid (Chang et al. 1996) and pig iliac arteries .
Adsense therapy
Antisense therapy is an attractive approach for angioplasty restenosis (reviewed in Bennet and Schwartz, 1995) . Several attempts to block the transcription of genes involved in cell replication have shown their efficacy in animal models of restenosis, although major concerns remain about the apparent nonspecificity of antisense oligonucleotides for their target mRNA.
Antisense approaches include oligonucleotides, antisense mRNA and autocatalytic ribozymes. Antisense oligonucleotides (ON) a~ short complementary DNA or RNA sequences that will hybridize to a specific mRNA forming a hybrid duplex. Two main mechanisms explain their action: 1) steric interferences to ribosome binding and translation or splice excision and 2) cleavage of mRNA by the nuclease RNase H which recognizes DNA-RNA duplexes. The advantages of antisense therapy include target specificity and ease of design and synthesis of oligonucleotides (ON) compared to any class of drugs. Uptake of (modified) oligonucleotides by cells is generally low and can be enhanced by complexing ON with liposomes or liposomes associated virus like the hemagglutinating virus of Japan (Morishita et al, 1993a; Morishita et al, 1994) . Targets for antisense agents include gene products shown to be critical to cell cycle progression like c-myc (Bennet et al, 1993) . c-myb (Simons et al, 1992) . cdc-2 (Morishita et al, 1993a) . cdk-2 (Morishita et al, 1994) . One critical limitation has been the rapid degradation of ON in the cell cytoplasm. Some chemical modifications have been proven to increase their stability (Wagner, 1994) . Methylphosphonate, phosphorothioate, phophoroamidate or phosphotriester linkages are some of these modifications. Specificity of ONs for their targets is another major concern. ON sequences must not be too long in order to limit nonspecific binding. The shortest continuous sequence required for uniqueness of an ON is 12 to 15 bases. The most common size used is between 15 to 20 bp. Short hybridized sequences, which may sometimes result from nonspecific binding, can be recognized and degraded by the RNase H. A third potential complication of ON therapy is the aptamer effect. ON can bind proteins (aptamers) and alter their functions which will result in nonspecific effects on cell morphology and proliferation. The aptamer effect has been particularly demonstrated with ON sequences that contain a stretch of 4 G residues (Villa et al, 1995) . Thus, the need for appropriate controls for antisense therapy has arisen. Recommended controls include not only sense, mismatched and scrambled sequences but also overexpression of the targeted mRNA or the protein to block the ON effect, measurements of mRNA and protein levels, the demonstration of a biological effect by multiple antisense sequences and the absence of biological effect for antisense ONs targeted to abundant genes not related to the one studied. Toxicity of antisense targeted to cell regulatory elements must be examined particularly in blood stem cells or other rapidly proliferating cells, like gastrointestinal cells, in case of systemic administration. Finally, the incorporation of degraded, chemically modified ON into the host genome may lead to a toxicity which has not been yet examined in detail.
THERAPEUTIC ANGIOCENESIS
It has been estimated that each year 150,000 patients require lower-limb amputations for ischemic disease in the United States. Their prognosis after amputation is even worse, and 50% of the patients will die in the 2 years following a major amputation (European Working Group on Critical Limb Ishemia, 1991). These statistics are explained in part by the lack of efficacious drug therapy. In spite of several improvements brought to these patients by new pharmacological compounds such as the prostanoids analogs, there is inadequate evidence to sup port the routine use of primary pharmacological treatment in patients with critical leg ischemia (European Working Group on Critical Limb Ishemia, 1991). Thus, alternative treatment strategies must be examined.
Therapeutic angiogenesis is a new strategy for the treatment of critical limb ischemia (Isner et al, 1995) . Recent investigations have established the feasibility of using recombinant formulations of angiogenic growth factors to augment collateral artery development in animal models of limb ischemia (Takeshita et al, 1994; Muhlhauser et al, 1995) . Overexpression of the fibroblast growth factor-1 (FGF-1) promotes intimal hyperplasia and angiogenesis in the arterial wall (Nabel et al, 1993~) . The vascular endothelial growth factor (VEGF), also known as vascular permeability factor or vasculotropin is a 32 to 42 kDa secreted glycoprotein (Connolly, 1991) . VEGF has specific effects on endothelial cells (Isner et al, 1995) . It is a potent mitogen and it increases cell membrane permeability. Intramuscular administration of VEGF protein induces dose-dependant collateral artery augmentation in a rabbit model of chronic limb ischemia (Takeshita et al, 1994) . Human umbilical vascular endothelial cells infected with a recombinant adenovirus expressing VEGF differentiated into capillary-like structures in vitro. Neovascularisation in the tissues surrounding the site of administration, after injection of this vector into mice was also observed (Muhlhauser et al. 1995) . Transfection of plasmid DNA encoding VEGF in a rabbit ischemic hind limb model using a hydrogel coated balloon catheter has resulted in stimulation of collateral flow, demonstrated by increased capillary density and increased distal blood pressure (Isner et al, 1995) . In addition VEGF administation promoted the recovery of disturbed endothelium-dependent flow (Bauters et al, 1995) . This approach is currently being investigated in a clinical trial in patients with severe lower extremity ischemia. In this study, the plasmid will be delivered proximal to the site of stenosis in an attempt to induce angiogenesis and relieve ischemic pain and trophic lesions (Isner et al, 1995) .
FUTURE DIRECTIONS
Recombinant genes can be expressed at local sites in arteries by gene transfer. This method permits high level and potentially long lasting local expression of recombinant proteins, and avoids systemic delivery of high concentrations of drugs which might have other systemic effects. There are a number of challenges which must be met prior to the broad application of gene or antisense therapy for cardiovascular diseases. These challenges include vector improvement and production, vector safety and therapeutic efficacy. At the present time, there are strong preclinical animal data suggesting a role for gene transfer in vascular cell proliferation and angiogenesis. Other potential targets for genetic treatment include thrombosis, cell adhesion, matrix synthesis and regulation of lipoprotein metabolism. These therapies could be applied to the treatment of graft occlusion, recurrent thrombosis and other vascular diseases.
